Report Sections

See All Reports

  • HP:0100806: Sepsis
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0100806: Sepsis

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (16)


    Name (Synonyms) Correlation
    drug2541 Plasma expansion with Ringer's Acetate Wiki 0.35
    drug3874 microcirculation recording Wiki 0.35
    drug3187 Storage of operating waste Wiki 0.35
    Name (Synonyms) Correlation
    drug564 COR-101 Wiki 0.35
    drug2158 Nitazoxanide with ivermectin Wiki 0.35
    drug2419 Phage Therapy Wiki 0.35
    drug3389 Toraymyxin PMX-20R (PMX Cartridge) Wiki 0.35
    drug176 Aerosolized All-Trans Retinoic acid plus oral Tamoxifen Wiki 0.35
    drug1884 MMR vaccine Wiki 0.35
    drug1746 LEAF-4L6715 Wiki 0.35
    drug45 2D Telemedicine Wiki 0.25
    drug51 3D Telemedicine Wiki 0.20
    drug3166 Standard treatment Wiki 0.13
    drug1705 Ivermectin Wiki 0.07
    drug333 Azithromycin Wiki 0.06
    drug2448 Placebo Wiki 0.03

    Correlated MeSH Terms (25)


    Name (Synonyms) Correlation
    D018805 Sepsis NIH 1.00
    D014115 Toxemia NIH 0.79
    D000071074 Neonatal Sepsis NIH 0.35
    Name (Synonyms) Correlation
    D019446 Endotoxemia NIH 0.35
    D011552 Pseudomonas Infections NIH 0.35
    D011645 Puerperal Infection NIH 0.35
    D066087 Perinatal Death NIH 0.35
    D063130 Maternal Death NIH 0.35
    D012772 Shock, Septic NIH 0.25
    D016470 Bacteremia NIH 0.25
    D011251 Pregnancy Complications, Infectious NIH 0.20
    D018746 Systemic Inflammatory Response Syndrome NIH 0.20
    D003643 Death, NIH 0.18
    D012769 Shock, NIH 0.13
    D058186 Acute Kidney Injury NIH 0.08
    D011024 Pneumonia, Viral NIH 0.04
    D011014 Pneumonia NIH 0.04
    D013577 Syndrome NIH 0.03
    D007239 Infection NIH 0.03
    D012127 Respiratory Distress Syndrome, Newborn NIH 0.03
    D055371 Acute Lung Injury NIH 0.03
    D012128 Respiratory Distress Syndrome, Adult NIH 0.03
    D003141 Communicable Diseases NIH 0.03
    D045169 Severe Acute Respiratory Syndrome NIH 0.01
    D018352 Coronavirus Infections NIH 0.01

    Correlated HPO Terms (4)


    Name (Synonyms) Correlation
    HP:0003811 Neonatal death HPO 0.35
    HP:0040187 Neonatal sepsis HPO 0.35
    HP:0001919 Acute kidney injury HPO 0.08
    Name (Synonyms) Correlation
    HP:0002090 Pneumonia HPO 0.04

    Clinical Trials

    Navigate: Correlations   HPO

    There are 8 clinical trials


    1 MR-Evaluation of Renal Function In Septic Patients

    A study of renal blood flow and renal oxygenation measured by magnetic resonance after a standardized fluid challenge in critically ill, resuscitated, patients with sepsis due to COVID-19 or other agents.

    NCT02765191
    Conditions
    1. Sepsis, Severe
    2. Acute Kidney Injury
    3. COVID-19
    Interventions
    1. Other: Plasma expansion with Ringer's Acetate
    MeSH:Sepsis Acute Kidney Injury
    HPO:Acute kidney injury Sepsis

    Primary Outcomes

    Description: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST), compared to baseline measurement

    Measure: Change in renal blood flow and renal oxygenation after standardized plasma expansion with fluid bolus

    Time: When achieved according to protocol, approximately 3-10 minutes after intervention

    Description: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST) during baseline measurement.

    Measure: Descriptive renal oxygenation and blood flow in critical illness due to sepsis

    Time: During Critical illness - at one time point

    Description: Measured with arterial spin labelling (ASL), Phase Contras, Blood oxygenation level dependent (BOLD) and T(2) -Relaxation-Under-Spin-Tagging (TRUST) images stratified in groups in regards to KDIGO grade during exam.

    Measure: Descriptive renal oxygenation and blood flow in critical illness in no/low grade AKI or high grade AKI.

    Time: During Critical illness - at one time point
    2 Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial

    Maternal and neonatal infections are among the most frequent causes of maternal and neonatal deaths, and current antibiotic strategies have not been effective in preventing many of these deaths. Recently, a randomized clinical trial conducted in a single site in The Gambia showed that treatment with oral dose of 2 g azithromycin vs. placebo for all women in labor reduced selected maternal and neonatal infections. However, it is unknown if this therapy reduces maternal and neonatal sepsis and mortality. The A-PLUS trial includes two primary hypotheses, a maternal hypothesis and a neonatal hypothesis. First, a single, prophylactic intrapartum oral dose of 2 g azithromycin given to women in labor will reduce maternal death or sepsis. Second, a single, prophylactic intrapartum oral dose of 2 g azithromycin given to women in labor will reduce intrapartum/neonatal death or sepsis.

    NCT03871491
    Conditions
    1. Maternal Death
    2. Maternal Infections Affecting Fetus or Newborn
    3. Neonatal SEPSIS
    4. Maternal Sepsis During Labor
    5. Neonatal Death
    6. Postpartum Sepsis
    Interventions
    1. Drug: Azithromycin
    2. Drug: Placebo
    MeSH:Infection Sepsis Toxemia Neonatal Sepsis Pregnancy Complications, Infectious Puerperal Infection Perinatal Death Maternal Death Death
    HPO:Neonatal death Neonatal sepsis Sepsis

    Primary Outcomes

    Description: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.

    Measure: Maternal: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.

    Time: within 6 weeks (42 days)

    Description: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group

    Measure: Neonatal: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group

    Time: 4 weeks (28 days) post-delivery

    Secondary Outcomes

    Description: Fever (>100.4°F/38°C) in addition to one or more of the following: fetal tachycardia ≥160 bpm, maternal tachycardia >100 bpm, tender uterus between contractions, or purulent/foul smelling discharge from uterus prior to delivery.

    Measure: Incidence of chorioamnionitis

    Time: prior to delivery

    Description: Fever (>100.4°F/38°C) in addition to one or more of maternal tachycardia >100 bpm, tender uterine fundus, or purulent/foul smelling discharge from uterus after delivery.

    Measure: Incidence of endometritis

    Time: within 42 days post-delivery

    Description: Wound infection (Purulent infection of a perineal or Cesarean wound with or without fever. In the absence of purulence, requires presence of fever >100.4°F/38°C and at least one of the following signs of local infection: pain or tenderness, swelling, heat, or redness around the incision/laceration); Abdominopelvic abscess (Evidence of pus in the abdomen or pelvis noted during open surgery, interventional aspiration or imaging); Pneumonia (Fever >100.4°F/38°C and clinical symptoms suggestive of lung infection including cough and/or tachypnea >24 breaths/min or radiological confirmation); Pyelonephritis (Fever >100.4°F/38°C and one or more of the following: urinalysis/dip suggestive of infection, costovertebral angle tenderness, or confirmatory urine culture); Mastitis/breast abscess or infection (Fever >100.4°F/38°C and one or more of the following: breast pain, swelling, warmth, redness, or purulent drainage).

    Measure: Incidence of other infections

    Time: within 42 days post-delivery

    Description: Use of subsequent maternal antibiotic therapy after randomization to 42 days postpartum for any reason.

    Measure: Incidence of use of subsequent maternal antibiotic therapy

    Time: after randomization to 42 days post-delivery

    Description: Time from drug administration until initial discharge after delivery (time may vary by site).

    Measure: Maternal initial hospital length of stay

    Time: within 42 days post-delivery

    Description: Maternal readmissions within 42 days of delivery

    Measure: Incidence of maternal readmissions

    Time: within 42 days post-delivery

    Description: Maternal admission to special care units

    Measure: Incidence of maternal admission to special care units

    Time: within 42 days post-delivery

    Description: Maternal unscheduled visit for care

    Measure: Incidence of maternal unscheduled visit for care

    Time: within 42 days post-delivery

    Description: Maternal GI symptoms including nausea, vomiting, and diarrhea and other reported side effects.

    Measure: Incidence of maternal GI symptoms

    Time: within 42 days post-delivery

    Description: Maternal death due to sepsis using the Global Network algorithm for cause of death

    Measure: Incidence of maternal death due to sepsis

    Time: within 42 days post-delivery

    Description: Incidence of other neonatal infections.

    Measure: Incidence of other neonatal infections (e.g. eye infection, skin infection)

    Time: within 42 days post-delivery

    Description: Neonatal initial hospital length of stay, defined as time of delivery until initial discharge (time may vary by site).

    Measure: Neonatal initial hospital length of stay

    Time: within 28 days of delivery

    Description: Neonatal readmissions within 42 days of delivery

    Measure: Incidence of neonatal readmissions

    Time: within 42 days of delivery

    Description: Neonatal admission to special care units

    Measure: Incidence of neonatal admission to special care units

    Time: within 28 days of delivery

    Description: Neonatal unscheduled visit for care

    Measure: Incidence of neonatal unscheduled visit for care

    Time: within 42 days post-delivery

    Description: Neonatal death due to sepsis using the Global Network algorithm for causes of death

    Measure: Incidence of neonatal death due to sepsis

    Time: within 28 days of delivery

    Description: Pyloric stenosis within 42 days of delivery, defined as clinical suspicion based on severe vomiting leading to death, surgical intervention (pyloromyotomy) as verified from medical records, or radiological confirmation.

    Measure: Incidence of pyloric stenosis within 42 days of delivery

    Time: within 42 days of delivery
    3 Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19

    Prospective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock

    NCT04352985
    Conditions
    1. Septic Shock
    2. Endoto
    3. Endotoxemia
    4. COVID
    5. Corona Virus Infection
    6. Sepsis, Severe
    Interventions
    1. Device: Toraymyxin PMX-20R (PMX Cartridge)
    MeSH:Shock, Septic Endotoxemia Sepsis Coronavirus Infections Severe Acute Respiratory Syndrome Shock
    HPO:Sepsis

    4 SQuISH-COVID: A Pilot Study

    This is a single-site prospective study to evaluate the diagnostic performance of the investigational SeptiScan System for patients presenting to the Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases.

    NCT04372472
    Conditions
    1. Sepsis
    2. COVID-19
    MeSH:Sepsis
    HPO:Sepsis

    Primary Outcomes

    Description: The SeptiScan System is an investigational microfluidic assay that measures the biophysical properties of human leukocytes as an aid, in conjunction with other clinical assessments, to detect life-threatening organ dysfunction caused by a dysregulated host immune response to infection. The SeptiScan System score is presented in three Interpretation Bands of low, intermediate, and high probability of disease. Remnant blood samples will be obtained from subjects in Emergency Department with signs or suspicion of COVID-19 or other infectious respiratory diseases. The blood samples will be analyzed using the SeptiScan System.

    Measure: To demonstrate the performance of the SeptiScan System as a diagnostic marker of life-threatening organ dysfunction caused by a dysregulated host immune response to infection.

    Time: Day of enrollment through Day 5
    5 A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes

    This is an open label phase II study of treatment with LEAF-4L6715 in patients who experience severe acute respiratory distress syndrome (ARDS) and are receiving artificial respiratory support due to COVID-19, Sepsis or other Causes. The purpose of this study is to evaluate the improvement in PaO2/FiO2 by more than 25% in patients treated with LEAF-4L6715.

    NCT04378920
    Conditions
    1. COVID19, Sepsis or Other Causes
    2. Acute Respiratory Distress Syndrome
    Interventions
    1. Drug: LEAF-4L6715
    MeSH:Sepsis Toxemia Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome
    HPO:Sepsis

    Primary Outcomes

    Measure: proportion of patients showing an increase of at least 25% of PaO2/FiO2 ratio

    Time: 24 hours

    Secondary Outcomes

    Measure: proportion of patients with a PaO2/FiO2 ratio above 200 mm Hg

    Time: 24, 48 and 72 hours

    Measure: all cause mortality

    Time: 28 days
    6 Use of a Live Attenuated Vaccine Repurposed as an Innate Immune-based Preventive Against COVID-19-associated Sepsis/Inflammation

    The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes that can prevent/dampen pathological inflammation and sepsis associated with COVID-19-infection, if exposed.

    NCT04475081
    Conditions
    1. Sepsis Syndrome
    Interventions
    1. Biological: MMR vaccine
    MeSH:Sepsis Toxemia Systemic Inflammatory Response Syndrome
    HPO:Sepsis

    Primary Outcomes

    Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

    Measure: Induction of myeloid-derived suppressor cells (MDSCs)

    Time: 14 days post-vaccination

    Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

    Measure: Induction of MDSCs

    Time: 30 days post vaccination

    Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

    Measure: Induction of MDSCs

    Time: 60 days post vaccination

    Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline

    Measure: Induction of MDSCs

    Time: 12 months post vaccination

    Secondary Outcomes

    Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

    Measure: COVID-19 infection positive

    Time: 14 days post-vaccination

    Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

    Measure: COVID-19 infection positive

    Time: 30 days post-vaccination

    Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

    Measure: COVID-19 infection positive

    Time: 60 days post-vaccination

    Description: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection

    Measure: COVID-19 infection positive

    Time: 12 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 14 days post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 30 days post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 60 days post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 3 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 4 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 5 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 6 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 7 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 8 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 9 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 10 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 11 months post-vaccination

    Description: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)

    Measure: Health questionnaire

    Time: 12 months post-vaccination
    7 Expanded Access Study of Phage Treatment in Covid-19 Patients on Anti-Microbials for Pneumonia or Bacteremia/Septicemia Due to A. Baumannii, P. Aeruginosa or S. Aureus

    Bacteriophage treatment in Covid-19 patients being treated with Anti-Microbials for Pneumonia or Bacteremia/Septicemia.

    NCT04636554
    Conditions
    1. Covid19
    2. Bacteremia
    3. Septicemia
    4. Acinetobacter Baumannii Infection
    5. Pseudomonas Aeruginosa Infection
    6. Staph Aureus Infection
    Interventions
    1. Other: Phage Therapy
    MeSH:Infection Communicable Diseases Bacteremia Pseudomonas Infections Sepsis Toxemia Pneumonia
    HPO:Pneumonia Sepsis

    8 Circulatory and Endothelial Coherence in COVID-19 and Non-COVID-19 Patients With Sepsis - Prospective, Observational Pilot Study

    This prospective observational pilot study investigates circulatory coherence in patients with COVID and non-COVID sepsis by comparison of microcirculation, endothelial glycocalyx, and clinical course

    NCT04644302
    Conditions
    1. Viral Pneumonia
    2. Sepsis
    Interventions
    1. Diagnostic Test: microcirculation recording
    MeSH:Sepsis Toxemia Pneumonia, Viral Pneumonia
    HPO:Pneumonia Sepsis

    Primary Outcomes

    Description: PPV describes microcirculation dysfunction

    Measure: change in Proportion of Perfused Vessels (PPV) parameter

    Time: 1st, 2nd and 3rd day

    Description: Syndecan-1 is a marker of endothelial glycocalyx

    Measure: change in Syndecan-1 serum concentration

    Time: 1st, 2nd and 3rd day

    Secondary Outcomes

    Description: albuminuria is a marker of glomerular endothelial cells dysfunction

    Measure: change in albuminuria

    Time: 1st, 2nd and 3rd day

    Description: mortality in 28 days from ICU admission

    Measure: mortality in 28 days

    Time: 30 days

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook